导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 31.56% | 78/4773 |
| 近一周 | -2.75% | 2991/5462 |
| 近一月 | -5.39% | 3212/5421 |
| 近一季 | -18.64% | 4747/5209 |
| 近半年 | 25.22% | 86/4920 |
| 近一年 | 48.47% | 76/4366 |
| 近两年 | 224.76% | 58/2954 |
| 近三年 | 215.60% | 10/2253 |
| 成立以来 | 127.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.15% 1361/4961 |
76.34% 193/5312 |
- - |
- - |
| 2025 | 91.90% 50/4813 |
-2.84% 2994/3635 |
6.29% 468/4076 |
74.32% 13/4524 |
6.60% 354/4813 |
| 2024 | 22.78% 367/3463 |
0.47% 970/2808 |
9.04% 59/3014 |
9.33% 2706/3129 |
2.51% 938/3463 |
| 2023 | 15.09% 39/2656 |
23.06% 121/2280 |
7.74% 27/2385 |
-12.34% 2116/2515 |
-0.97% 274/2655 |
| 2022 | -36.02% 1736/2207 |
-26.92% 1797/1919 |
3.23% 1187/2016 |
-18.70% 1731/2113 |
4.32% 561/2208 |
| 2021 | 6.03% 528/1822 |
-15.54% 1192/1255 |
20.35% 148/1330 |
-9.75% 1192/1466 |
15.59% 61/1822 |
| 2020 | 17.71% 759/1250 |
0.15% 170/1028 |
26.12% 148/1067 |
-5.37% 1111/1164 |
-1.52% 1108/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证5G通信主题ETF联接C VS. 长安沪深300非周期A(740101) |